Articles related to EARLY DETECTION

Prostate cancer screening continues to rely on individualized risk assessment, PSA monitoring, and shared decision-making, while advances in MRI imaging and biomarker testing may help refine biopsy decisions and reduce unnecessary invasive procedures.

The FDA approved Freenome’s SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults. Clinical study results showed the test detected roughly 80% of colorectal cancers, though current guidelines continue to favor colonoscopy and stool-based screening options.

A two-year analysis of 12,670 screened men found that the Stockholm3 risk model detected more clinically significant prostate cancers than PSA testing alone, primarily through fewer false-negative results. The findings suggest improved screening discrimination, although follow-up remains limited to two years.

A multivariable screening test detects 90% of clinically significant prostate cancers vs 74% with PSA alone, suggesting PSA thresholds may miss aggressive disease despite similar false-positive rates.

Survey responses from 5,797 Fox Insight participants suggest sleep disturbances, autonomic dysfunction, and emotional changes preceded Parkinson’s disease diagnosis by more than a decade in a substantial proportion of respondents.

The American Cancer Society updated its colorectal cancer screening guidelines to include two new multitarget stool tests and a blood-based option, while maintaining colonoscopy as the gold standard and the age-45 screening initiation recommendation for average-risk adults.